IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
Clinical trial NCT03562871 · COMPLETED
Trial details
- NCT number
- NCT03562871
- Sponsor
- IO Biotech
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-22
- Primary completion
- 2021-02-06
- Enrollment
- 109
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.